ArQule: Buy the Dip?
The pharma company has wowed investors with solid clinical data multiple times this year.
ArQule
ARQL
ARQL
$9.53
$0.40
4.4%
BATS BZX Real Time Price as of October 21, 2019, 4:00 p.m. EDT
View Interactive ARQL Charts
A clinical-stage biotechnology company, engaged in the research and development of cancer therapeutics. Its mission is to research, develop and commercialize targeted cancer drugs with reduced toxicities compared to conventional cancer chemotherapeutics.
News & Analysis: ArQule
Arqule Inc (ARQL) Q2 2019 Earnings Call Transcript
ARQL earnings call for the period ending June 30, 2019.
5 Best Biotech Stocks of 2019 So Far
These biotech stocks have at least quadrupled in just over six months this year.
Here's Why ArQule Jumped 53.1% in June
The pharmaceutical pipeline shined, and the business doubled its cash position.
Here's the Surprising Reason ArQule Shares Rose as Much as 11% Today
Investors are increasingly optimistic about the company.
Here's Why ArQule Is Soaring Again Today
A new day, a new batch of promising interim data from an early-stage clinical study.
Here's Why ArQule Shares Rose as Much as 44.7% Today
The stock soared to its highest level in over 10 years on encouraging, early-stage clinical results.
Stock Market News: Chewy Goes Public; ArQule Soars on Cancer Study
Stocks were poised to ease lower on Friday morning.
Arqule Inc (ARQL) Q1 2019 Earnings Call Transcript
ARQL earnings call for the period ending March 31, 2019.
Here's Why ArQule Rose as Much as 12.7% Today
The oncology-focused pharma announced first-quarter 2019 operating results.
